Pasritamig not checked

Coherus Oncology, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
An antibody built to latch onto two or more targets at once.-mig: multi-specific immunoglobulins WHO name stem
Tested for
Solid Tumor
Main trialPhase 1/2
“The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.”In the company’s words, NCT07945821 on ClinicalTrials.gov

Other drugs for Solid Tumor

All 2440 drugs for Solid Tumor

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Aug 2028 A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pasritamig

Following is part of Solo: you see every change to Pasritamig the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in